

# Peter C Hollenhorst

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3350840/publications.pdf>

Version: 2024-02-01

35  
papers

2,407  
citations

394421

19  
h-index

477307

29  
g-index

36  
all docs

36  
docs citations

36  
times ranked

4250  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells. PLoS Genetics, 2021, 17, e1009708.	3.5	7
2	Androgen signaling connects short isoform production to breakpoint formation at Ewing sarcoma breakpoint region 1. NAR Cancer, 2021, 3, zcab033.	3.1	3
3	Toll-like receptor 4 signaling activates ERG function in prostate cancer and provides a therapeutic target. NAR Cancer, 2021, 3, zcaa046.	3.1	7
4	AAA high-throughput screen identifies inhibitors of the interaction between the oncogenic transcription factor ERG and the cofactor EWS. PLoS ONE, 2020, 15, e0238999.	2.5	2
5	4296 Targeting ERG Through Toll-Like Receptor 4 in Prostate Cancer. Journal of Clinical and Translational Science, 2020, 4, 17-17.	0.6	0
6	Title is missing!. , 2020, 15, e0238999.		0
7	Title is missing!. , 2020, 15, e0238999.		0
8	Title is missing!. , 2020, 15, e0238999.		0
9	Title is missing!. , 2020, 15, e0238999.		0
10	Oncogenic ETS Factors in Prostate Cancer. Advances in Experimental Medicine and Biology, 2019, 1210, 409-436.	1.6	34
11	ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase. Cancer Letters, 2018, 414, 190-204.	7.2	41
12	Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUNα-FOS at composite DNA sites. Journal of Biological Chemistry, 2018, 293, 18624-18635.	3.4	13
13	Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 5977-5989.	7.0	58
14	Common ELF1 deletion in prostate cancer bolsters oncogenic ETS function, inhibits senescence and promotes docetaxel resistance. Genes and Cancer, 2018, 9, 198-214.	1.9	16
15	Genome-Wide Analysis of RAS/ERK Signaling Targets. Methods in Molecular Biology, 2017, 1487, 277-288.	0.9	1
16	EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Research, 2017, 77, 6651-6666.	0.9	66
17	Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation. Journal of Biological Chemistry, 2017, 292, 17225-17235.	3.4	17
18	Interaction with ZMYND11 mediates opposing roles of Ras-responsive transcription factors ETS1 and ETS2. Nucleic Acids Research, 2017, 45, gkx039.	14.5	14

#	ARTICLE	IF	CITATIONS
19	An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer. <i>Cell Reports</i> , 2016, 17, 1289-1301.	6.4	38
20	Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells. <i>Cell Communication and Signaling</i> , 2015, 13, 12.	6.5	63
21	Extracellular Signal-Regulated Kinase Signaling Regulates the Opposing Roles of JUN Family Transcription Factors at ETS/AP-1 Sites and in Cell Migration. <i>Molecular and Cellular Biology</i> , 2015, 35, 88-100.	2.3	21
22	ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells. <i>Nucleic Acids Research</i> , 2014, 42, 11928-11940.	14.5	100
23	Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation. <i>Molecular Cancer</i> , 2014, 13, 61.	19.2	31
24	RAS/ERK pathway transcriptional regulation through ETS/AP-1 binding sites. <i>Small GTPases</i> , 2012, 3, 154-158.	1.6	37
25	At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. <i>Odontology / the Society of the Nippon Dental University</i> , 2012, 100, 109-129.	1.9	14
26	Abstract PR1: Oncogenic ETS over-expression mimics RAS/MAPK signaling in prostate cells. <i>Cancer Research</i> , 2012, 72, PR1-PR1.	0.9	0
27	Genomic and Biochemical Insights into the Specificity of ETS Transcription Factors. <i>Annual Review of Biochemistry</i> , 2011, 80, 437-471.	11.1	425
28	Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. <i>Genes and Development</i> , 2011, 25, 2147-2157.	5.9	138
29	The ETS Gene ETV4 Is Required for Anchorage-Independent Growth and a Cell Proliferation Gene Expression Program in PC3 Prostate Cells. <i>Genes and Cancer</i> , 2010, 1, 1044-1052.	1.9	53
30	Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 620-628.	8.2	234
31	DNA Specificity Determinants Associate with Distinct Transcription Factor Functions. <i>PLoS Genetics</i> , 2009, 5, e1000778.	3.5	161
32	Microsatellites as EWS/FLI response elements in Ewing's sarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10149-10154.	7.1	246
33	Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. <i>Genes and Development</i> , 2007, 21, 1882-1894.	5.9	253
34	Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. <i>Nucleic Acids Research</i> , 2004, 32, 5693-5702.	14.5	179
35	Forkhead Genes in Transcriptional Silencing, Cell Morphology and the Cell Cycle: Overlapping and Distinct Functions for FKH1 and FKH2 in <i>Saccharomyces cerevisiae</i> . <i>Genetics</i> , 2000, 154, 1533-1548.	2.9	135